Skip to main content

EUROpean consortium for antiCALINs as next generation high-affinity protein therapeutics

Ziel

The consortium aims to develop and produce an Anticalin, a member of a novel high-affinity scaffold derived from the lipocalin protein family. The Anticalin is specific for hepcidin which is a central regulator of iron homeostasis, and will be used to antagonize hepcidin for the treatment of “anemia of chronic disease” (ACD). Anticalins are genetically modified lipocalins that can target almost any desired molecule. Unlike Immunoglobulins, they can be produced at low cost in microbial expression systems, are expected to be non immunogenic and offer therapeutic advantages where antibody effector functions are not desired. ACD, the most frequent anemia in hospitalized patients, develops in subjects suffering from infections, inflammatory and auto-immune disease, cancer and chronic kidney disease. It is often successfully treated by administering Erythropoiesis-Stimulating Agents. However, a significant number of patients are hypo- or non-responsive to ESA. Anti-hepcidin therapies, alone or together with ESAs, may improve anemia and the patients’ erythropoietic response and enable the use of no or even much lower ESA doses, avoiding the potential detrimental effects of high doses of ESA. The Consortium has already generated proof-of-concept data in an animal model with early candidates. The project aims at identifying, validating, and developing a specific, high affinity drug candidate based on the lipocalin scaffold as promising alternatives to immunoglobulins and a therapeutic approach based on the neutralization of hepcidin. Animal models will be developed and utilized to characterize pharmacokinetic and pharmacodynamic relationships, optimize dosing, to determine safety, biomarker responses and potential synergy with ESA’s. Furthermore, production processes will be optimized leading to a scalable GMP process which provides material for preclinical and clinical studies to establish the safety, tolerability, and PK/PD of an Anticalin hepcidin blocker (Phase Ia/b).

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2011-two-stage
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

CP-FP - Small or medium-scale focused research project

Koordinator

PIERIS PHARMACEUTICALS GMBH
Adresse
Lise-meitner-straße 30
85354 Freising
Deutschland
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU-Beitrag
€ 2 164 000
Kontakt Verwaltung
Rita Fischer (Mrs.)

Beteiligte (10)

TECHNISCHE UNIVERSITAET MUENCHEN
Deutschland
EU-Beitrag
€ 261 600
Adresse
Arcisstrasse 21
80333 Muenchen
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Ulrike Ronchetti (Ms.)
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Österreich
EU-Beitrag
€ 416 200
Adresse
Christoph Probst Platz 1
6020 Innsbruck
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Guenter Weiss (Prof.)
STICHTING RADBOUD UNIVERSITEIT
Niederlande
EU-Beitrag
€ 494 340
Adresse
Houtlaan 4
6525 XZ Nijmegen
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Maarten Van Langen (Mr.)
COVANCE LABORATORIES LTD
United Kingdom
EU-Beitrag
€ 456 800
Adresse
Otley Road
HG3 IPY Harrogate
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Carol Noble (Ms.)
ANTITOPE LIMITED
United Kingdom
EU-Beitrag
€ 263 040
Adresse
Babraham Research Campus
CB22 3AT Cambridge
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Frank Carr (Dr.)
FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED
United Kingdom
EU-Beitrag
€ 1 109 963,50
Adresse
Belasis Avenue
TS23 1LH Billingham
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Lyons Mike (Mr.)
CORIOLIS PHARMASERVICE GMBH

Beteiligung beendet

Deutschland
EU-Beitrag
€ 92 734,16
Adresse
Am Klopferspitz 19
82152 Martinsried
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Thomas Wiggenhorn
FGK CLINICAL RESEARCH GMBH
Deutschland
EU-Beitrag
€ 271 200
Adresse
Heimeranstrasse 35
80339 Munchen
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Ina Ott (Mrs.)
CONSULTECH TECHNOLOGIEBERATUNG GMBH
Deutschland
EU-Beitrag
€ 309 800
Adresse
Morgensternstrasse 24
12207 Berlin
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Daniel Schubart (Dr.)
CORIOLIS PHARMA RESEARCH GMBH*
Deutschland
EU-Beitrag
€ 156 625,84
Adresse
Am Klopferspitz 19
82152 Martinsried
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Thomas Wiggenhorn